Araclon Biotech S.L.

<div class="infobox infobox-company">
<div class="infobox-header">Araclon Biotech S.L.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Zaragoza, Spain</div>
<div class="infobox-row"><strong>Founded:</strong> 2008</div>
<div class="infobox-row"><strong>Parent Company:</strong> Grifols</div>
<div class="infobox-row"><strong>Private:</strong> Wholly-owned subsidiary</div>
<div class="infobox-row"><strong>Status:</strong> Active</div>
</div>

Overview

<div class="infobox infobox-company">
<div class="infobox-header">Araclon Biotech S.L.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Zaragoza, Spain</div>
<div class="infobox-row"><strong>Founded:</strong> 2008</div>
<div class="infobox-row"><strong>Parent Company:</strong> Grifols</div>
<div class="infobox-row"><strong>Private:</strong> Wholly-owned subsidiary</div>
<div class="infobox-row"><strong>Status:</strong> Active</div>
</div>

Overview

Araclon Biotech is a Spanish biotechnology company focused on the development of therapies and diagnostic tools for [Alzheimer's disease](/diseases/alzheimers-disease). Founded in 2008 and headquartered in Zaragoza, Spain, the company is a wholly-owned subsidiary of Grifols, a leading global healthcare company known for its plasma-derived products["@araclon"].

Araclon takes a distinctive approach to Alzheimer's disease therapy by focusing on the [amyloid-beta](/proteins/amyloid-beta) 40 (Abeta40) isoform rather than the more commonly targeted Abeta42. This differentiated strategy may offer advantages in safety and efficacy, as Abeta40 is the most abundant isoform in the brain and may play a distinct pathological role["@alzheimers2020"].

Company Background

Ownership and Structure

Araclon operates as a fully integrated subsidiary of Grifols, benefiting from:

• Access to Grifols' plasma fractionation infrastructure
• Manufacturing capabilities for biological products
• Global commercial network
• Financial resources for clinical development

Strategic Focus

Araclon's mission is to develop disease-modifying therapies for Alzheimer's disease through:

Pipeline / Products

ABvac40 - Lead Vaccine Candidate

ABvac40 is Araclon's lead clinical candidate, an active immunotherapy vaccine targeting amyloid-beta 40[@abvac].

| Attribute | Details |
|-----------|---------|
| Type | Active immunotherapy (vaccine) |
| Target | Amyloid-beta 40 (Aβ40) |
| Mechanism | Generates anti-Aβ40 antibodies |
| Indication | Alzheimer's Disease (early/mild) |
| Route | Subcutaneous injection |
| Development Phase | Phase 2 |
| Status | Active clinical development |

Why Aβ40?
Most Alzheimer's immunotherapy programs target Aβ42, the less abundant isoform. Araclon's focus on Aβ40 represents a differentiated approach:

• Aβ40 is the most abundant amyloid-beta species in the brain
• Aβ40 may be more directly linked to vascular amyloid (CAA)
• Targeting Aβ40 may avoid some Aβ42-specific toxicities
• Potential for better safety profile

Clinical Development:

• Phase 1 (2016-2020): Completed first-in-human study demonstrating safety and immunogenicity
• Phase 2 (2021-): Ongoing in early Alzheimer's disease patients

AR-1801 - Antibody Program

AR-1801 is a monoclonal antibody targeting amyloid-beta, in preclinical development[@program].

| Attribute | Details |
|-----------|---------|
| Type | Monoclonal antibody (passive immunotherapy) |
| Target | Amyloid-beta |
| Indication | Alzheimer's Disease |
| Development Phase | Preclinical |
| Status | Active research |

Diagnostic Assays

Araclon has developed CSF (cerebrospinal fluid)-based biomarker assays for Alzheimer's disease diagnosis[@araclona].

| Product | Target | Application |
|---------|--------|-------------|
| Aβ40 ELISA | Amyloid-beta 40 | AD diagnosis |
| Aβ42 ELISA | Amyloid-beta 42 | AD diagnosis |
| Total tau | [Tau protein](/proteins/tau) | Neurodegeneration marker |
| Phospho-tau | Phosphorylated tau | AD diagnosis |

These diagnostic tools support patient selection and monitoring in clinical trials.

Technology Platform

Immunotherapy Approach

Araclon develops both active and passive immunization strategies:

Active Immunization (Vaccines):

• Stimulates patient's own immune system
• Long-lasting antibody production
• Lower cost per treatment
• Requires robust immune response

• Direct antibody administration
• Predictable dosing
• Suitable for patients with compromised immunity
• Higher manufacturing costs

Differentiated Aβ40 Targeting

Araclon's focus on Aβ40 offers several potential advantages:

Clinical Evidence

ABvac40 Phase 1 Results

The Phase 1 trial demonstrated[@abvaca]:

• Safety: Good tolerability with no serious adverse events related to the vaccine
• Immunogenicity: Robust antibody responses in >90% of patients
• Pharmacokinetics: Dose-dependent antibody levels maintained over treatment period
• Biomarkers: Trend toward reduced CSF Aβ40 in treatment arm

Phase 2 Development

The ongoing Phase 2 trial is evaluating:

• Clinical efficacy (cognitive endpoints)
• Biomarker effects (CSF Aβ40, tau)
• Safety in larger patient population

Market Context

Alzheimer's Disease Market

Alzheimer's disease represents one of the largest unmet medical needs:

• Prevalence: ~6 million patients in the US, >55 million globally
• Current treatments: Only symptomatic therapies (AChE inhibitors, memantine)
• Disease-modifying therapies: Leqembi (Biogen/Eisai) approved 2023, [Donanemab](/entities/donanemab) (Eli Lilly) pending

Competitive Landscape

| Company | Drug | Target | Stage |
|---------|------|--------|-------|
| Biogen/Eisai | Leqembi (Lecanemab) | Aβ protofibrils | Approved |
| Eli Lilly | Donanemab | Aβ plaque | Approved |
| Roche | Gantenerumab | Aβ plaque | Phase 3 |
| Araclon | ABvac40 | Aβ40 | Phase 2 |
| Prothena | PRX012 | Aβ | Phase 1 |

Funding & Financials

Araclon is funded through its parent company Grifols:

• Strategic investment in Alzheimer's R&D
• Access to Grifols' manufacturing infrastructure
• No external fundraising required

Key People

• Dr. Pablo Martínez (Director General) - Leadership in biotech operations
• Dr. Manuel J. Sarasa (Scientific Director) - Expert in amyloid biology

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Araclon Biotech S.L. discovered through SciDEX knowledge graph analysis: